Skip to main content

Table 1 Baseline characteristics of study patients stratified by the primary outcome

From: Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study

  Overall
(N = 3972)
Survivors
(N = 3747)
Non-survivors
(N = 225)
P-value
Age, years 59.0 ± 11.9 58.4 ± 11.8 68.4 ± 10.6 < 0.001
Male sex, n (%) 3132 (78.8) 2993 (79.9) 139 (61.8) < 0.001
Diabetes mellitus, n (%) 1299 (32.7) 1207 (32.2) 92 (40.9) 0.007
Hypertension, n (%) 2429 (61.2) 2262 (60.4) 167 (74.2) < 0.001
Peripheral artery diseases, n (%) 159 (4.0) 141 (3.8) 18 (8.0) 0.002
Previous CABG or PCI, n (%) 583 (14.7) 548 (14.6) 35 (15.6) 0.702
STEMI, n (%) 3467 (87.3) 3269 (87.2) 198 (88.0) 0.741
Tumor diseases, n (%) 81 (2.0) 71 (1.9) 10 (4.4) 0.009
Liver diseases, n (%) 570 (14.8) 555 (14.8) 15 (6.7) 0.001
COPD, n (%) 32 (0.8) 27 (0.7) 5 (2.2) 0.014
Hemodynamics     
Heart rate, bpm 77.4 ± 15.2 77.0 ± 14.9 83.4 ± 19.7 < 0.001
Systolic blood pressure, mmHg 124.7 ± 18.3 124.8 ± 18.1 123.0 ± 21.9 0.157
EF, % 53.8 ± 7.6 54.1 ± 7.4 48.6 ± 9.2 < 0.001
Cardiac arrest, n (%) 144 (3.6) 125 (3.3) 19 (8.4) < 0.001
Laboratory tests     
D-dimer, ng/mL 330 (220–590) 330 (220–550) 600 (320–1240) < 0.001
LDL-C, mmol/L 2.7 ± 0.9 2.7 ± 0.9 2.7 ± 0.9 0.331
hsCRP, mg/L 7.16 (2.75–12.03) 7.00 (2.71–11.94) 11.17 (3.88–13.13) < 0.001
Creatinine, µmoI/L 82.0 ± 25.1 81.0 ± 22.8 98.1 ± 47.1 < 0.001
Peak cTnI, ng/mL 2.50 (0.44–10.80) 2.48 (0.44–10.62) 2.97 (0.62–14.01) 0.093
GRACE score 109.7 ± 27.7 107.7 ± 25.9 142.0 ± 35.0 < 0.001
TIMI score 6.3 ± 1.8 6.2 ± 1.8 8.0 ± 2.0 < 0.001
Findings and details of PCI procedures
Culprit lesion, n (%)     
Left main artery 95 (2.4) 80 (2.1) 15 (6.7) < 0.001
Left anterior descending artery 1734 (43.7) 1632 (43.6) 102 (45.3)  
Left circumflex 610 (15.4) 592 (15.8) 18 (8.0)  
Right coronary artery 1515 (38.1) 1429 (38.1) 86 (38.2)  
Bypass graft 18 (0.5) 14 (0.4) 4 (1.8)  
Multi-vessel disease, n (%)     
1-vessel disease 1002 (25.2) 966 (25.8) 36 (16.0) < 0.001
2-vessel disease 1253 (31.6) 1201 (32.1) 52 (23.1)  
3-vessel disease 1717 (43.2) 1580 (42.2) 137 (60.9)  
Pre-PCI TIMI 0 flow, n (%) 2607 (65.6) 2441 (65.2) 166 (73.8) 0.008
Post-PCI TIMI 3 flow, n (%) 3822 (96.2) 3617 (96.5) 205 (91.1) < 0.001
D2B time, mins 128 (95–202) 128 (95–201) 125 (90–219) 0.342
Stent placements, n (%) 3497 (88.0) 3321 (88.6) 176 (78.2) < 0.001
Thrombus aspiration, n (%) 1649 (41.5) 1561 (41.7) 88 (39.1) 0.451
IABP, n (%) 381 (9.6) 323 (8.6) 58 (25.8) < 0.001
Glycoprotein IIb/IIIa inhibitor, n (%) 534 (13.4) 507 (13.5) 27 (12.0) 0.513
Complete revascularization
before discharge, n (%)
1731 (43.6) 1669 (44.5) 62 (27.6) < 0.001
Medications a     
Aspirin, n (%) 3930 (98.9) 3718 (99.2) 212 (94.2) < 0.001
P2Y12 inhibitors, n (%) 3936 (99.1) 3719 (99.3) 217 (96.4) < 0.001
Statins, n (%) 3708 (93.4) 3507 (93.6) 201 (89.3) 0.013
  1. a Medication typically referred to drugs prescribed at discharge, or otherwise, drugs being used during hospitalization if patients failed to survive the hospitalization. bpm = beats per minutes, CABG = Coronary artery bypass grafting, COPD = chronic obstructive pulmonary diseases, cTnI = cardiac troponin I, D2B time = door-to-balloon time, EF = ejection fraction, GRACE score = the Global Registry of Acute Coronary Events risk score, hsCRP = high sensitivity C-reactive protein, IABP = intra-aortic balloon pump, LDL-C = low-density lipoprotein cholesterol, PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction, TIMI flow = the Thrombolysis In Myocardial Infarction grade flow, TIMI score = the Thrombolysis In Myocardial Infarction risk score